Arca
Skip to content
Tools
Tools

Colorectal carcinoma

Drug research and approvals for colorectal carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,173 studies of colorectal carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 1,173
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 1,173 recruiting on ClinicalTrials.gov ↗

How its trials ended

4,766 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 962 whose ending is known, 34% met their primary endpoint, 13% missed it and 53% stopped early.

  • Completed, result not reported1,71436%
  • Ongoing1,25926%
  • Status unknown83117%
  • Met its primary endpoint3307%
  • Stopped: other or unclear2495%
  • Stopped: enrollment or feasibility1303%
  • Missed its primary endpoint1223%
  • Stopped: sponsor or business decision701%
  • Stopped: lack of efficacy411%
  • Stopped: funding15<1%
  • Stopped: safety5<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 11, 2025In vivo lung perfusion (IVLP) as an adjuvant treatment for patients with resectable or unresectable pulmonary metastases of colorectal carcinomasOxaliplatin / Methylprednisolone / Cefazolin / Heparin / Human serum albuminUniversity Health NetworkClosed
Jun 5, 2024A phase 1a/1b, first-in-human, multicenter study to assess the efficacy and safety of RGT-61159 for treatment of patients with relapsed/refractory adenoid…RGT-61159Rgenta Therapeutics Inc.Ongoing
Nov 22, 2022A phase 1 study of BMS-986360/CC-90001 alone and in combination with chemotherapy or nivolumab in advanced solid tumorsCC-90001 (BMS-986360) / Nivolumab / Docetaxel / CapecitabineBristol-Myers SquibbClosed
Feb 24, 2021In vivo lung perfusion (IVLP) as an adjuvant treatment for patients with resectable or unresectable pulmonary metastases of colorectal carcinomasOxaliplatinUniversity Health NetworkOngoing
Mar 9, 2016A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with…Ciforadenant (CPI-444) / AtezolizumabCorvus PharmaceuticalsClosed
Dec 23, 2015A phase III study of pembrolizumab (MK-3475) vs chemotherapy in microsatellite instability-high (msi-h) or mismatch repair deficient (DMMR) stage iv colorectal…KeytrudaMerck & Co. (MSD)Ongoing
Sep 30, 2015A phase II study of pembrolizumab (MK-3475) as monotherapy in subjects with previously treated locally advanced unresectable or metastatic (stage iv)…KeytrudaMerck & Co. (MSD)Ongoing
Aug 14, 2013A phase 1 study to evaluate the safety, tolerability and efficacy of MK-8353 combination therapies in subjects with advanced solid tumorsMK-8353/ Ridaforolimus (MK-8669)/ Pembrolizumab (MK-3475)Merck & Co. (MSD)Pending

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Feb 6, 1990Indium In-111 altumomab pentetateDetection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma.Hybritech, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.